S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
25 Ways to Improve Your Financial Situation in 1 Hour
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
La-Z-Boy Reclines To More Comfortable Levels 
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
China Threat Triggers Potential Mining Boom for Investors (Ad)
US stocks lose ground in uneven trading to open December
US employers added a strong 263,000 jobs in November in face of surging rate hikes by Fed
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
25 Ways to Improve Your Financial Situation in 1 Hour
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
La-Z-Boy Reclines To More Comfortable Levels 
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
China Threat Triggers Potential Mining Boom for Investors (Ad)
US stocks lose ground in uneven trading to open December
US employers added a strong 263,000 jobs in November in face of surging rate hikes by Fed
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
25 Ways to Improve Your Financial Situation in 1 Hour
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
La-Z-Boy Reclines To More Comfortable Levels 
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
China Threat Triggers Potential Mining Boom for Investors (Ad)
US stocks lose ground in uneven trading to open December
US employers added a strong 263,000 jobs in November in face of surging rate hikes by Fed
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
25 Ways to Improve Your Financial Situation in 1 Hour
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
La-Z-Boy Reclines To More Comfortable Levels 
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
China Threat Triggers Potential Mining Boom for Investors (Ad)
US stocks lose ground in uneven trading to open December
US employers added a strong 263,000 jobs in November in face of surging rate hikes by Fed
NASDAQ:NPCE

NeuroPace - NPCE Stock Forecast, Price & News

$1.59
-0.02 (-1.24%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.57
$1.69
50-Day Range
$1.48
$3.75
52-Week Range
$1.38
$12.06
Volume
23,201 shs
Average Volume
156,603 shs
Market Capitalization
$39.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.38

NeuroPace MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
489.6% Upside
$9.38 Price Target
Short Interest
Bearish
6.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.23mentions of NeuroPace in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$491,840 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.97) to ($1.86) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

525th out of 1,052 stocks

Surgical & Medical Instruments Industry

58th out of 104 stocks

NPCE stock logo

About NeuroPace (NASDAQ:NPCE) Stock

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.

Receive NPCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroPace and its competitors with MarketBeat's FREE daily newsletter.

NPCE Stock News Headlines

Massive Insider Trade At NeuroPace
Neuropace, Inc. (NPCE) Q3 2022 Earnings Call Transcript
NeuroPace Third Quarter 2022 Earnings: Beats Expectations
NeuroPace, Inc. (NPCE)
NeuroPace Inc - Stock Quote NPCE
5 Analysts Have This to Say About NeuroPace
See More Headlines
Receive NPCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroPace and its competitors with MarketBeat's FREE daily newsletter.

NPCE Company Calendar

Last Earnings
11/08/2022
Today
12/02/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/09/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NPCE
Fax
N/A
Employees
166
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.38
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$3.50
Forecasted Upside/Downside
+489.6%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$-36,080,000.00
Net Margins
-106.63%
Pretax Margin
-106.63%

Debt

Sales & Book Value

Annual Sales
$45.18 million
Book Value
$1.74 per share

Miscellaneous

Free Float
22,313,000
Market Cap
$39.59 million
Optionable
Not Optionable
Beta
0.72

Key Executives

  • Mr. Michael L. Favet (Age 52)
    Pres, CEO & Director
    Comp: $835.42k
  • Ms. Irina RidleyMs. Irina Ridley (Age 36)
    Gen. Counsel & Corp. Sec.
    Comp: $462.11k
  • Dr. Martha J. Morrell (Age 65)
    Chief Medical Officer
    Comp: $583.5k
  • Ms. Rebecca L. Kuhn (Age 61)
    CFO, VP of Fin. & Admin. and Assistant Sec.
  • Ms. Chi Nguyen (Age 45)
    VP of Marketing
  • Mr. Mark S. Saxton (Age 57)
    VP of Sales
  • Ms. Irene Thomas (Age 53)
    VP of HR
  • Mr. Andre G. Marquette
    Chief Commercial Officer













NPCE Stock - Frequently Asked Questions

Should I buy or sell NeuroPace stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeuroPace in the last twelve months. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NPCE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NPCE, but not buy additional shares or sell existing shares.
View NPCE analyst ratings
or view top-rated stocks.

What is NeuroPace's stock price forecast for 2023?

4 equities research analysts have issued 12 month target prices for NeuroPace's stock. Their NPCE share price forecasts range from $3.50 to $13.00. On average, they predict the company's share price to reach $9.38 in the next year. This suggests a possible upside of 489.6% from the stock's current price.
View analysts price targets for NPCE
or view top-rated stocks among Wall Street analysts.

How have NPCE shares performed in 2022?

NeuroPace's stock was trading at $10.08 on January 1st, 2022. Since then, NPCE stock has decreased by 84.2% and is now trading at $1.59.
View the best growth stocks for 2022 here
.

When is NeuroPace's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our NPCE earnings forecast
.

How were NeuroPace's earnings last quarter?

NeuroPace, Inc. (NASDAQ:NPCE) issued its quarterly earnings results on Tuesday, November, 8th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.04. The firm earned $11.16 million during the quarter, compared to analysts' expectations of $10.32 million. NeuroPace had a negative trailing twelve-month return on equity of 80.18% and a negative net margin of 106.63%.

What guidance has NeuroPace issued on next quarter's earnings?

NeuroPace issued an update on its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $44.50 million-$45.50 million, compared to the consensus revenue estimate of $43.97 million.

When did NeuroPace IPO?

(NPCE) raised $85 million in an initial public offering on Thursday, April 22nd 2021. The company issued 5,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo and SVB Leerink were co-managers.

What is NeuroPace's stock symbol?

NeuroPace trades on the NASDAQ under the ticker symbol "NPCE."

Who are NeuroPace's major shareholders?

NeuroPace's stock is owned by a variety of retail and institutional investors. Top institutional investors include Nantahala Capital Management LLC (1.78%), Bellevue Group AG (1.56%), Revelation Capital Management LLC (0.17%) and Financial Advocates Investment Management (0.04%). Insiders that own company stock include Accelmed Partners Ii LP, Frank M Fischer, Irina Ridley and Orbimed Advisors Llc.
View institutional ownership trends
.

How do I buy shares of NeuroPace?

Shares of NPCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NeuroPace's stock price today?

One share of NPCE stock can currently be purchased for approximately $1.59.

How much money does NeuroPace make?

NeuroPace (NASDAQ:NPCE) has a market capitalization of $39.60 million and generates $45.18 million in revenue each year. The company earns $-36,080,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis.

How many employees does NeuroPace have?

The company employs 166 workers across the globe.

How can I contact NeuroPace?

The official website for the company is www.neuropace.com. The company can be reached via phone at 650-237-2700 or via email at investors@neuropace.com.

This page (NASDAQ:NPCE) was last updated on 12/2/2022 by MarketBeat.com Staff